Hylly
Henkilönnimi England, Paul, kirjoittaja.
Nimeke- ja vastuullisuusmerkintö Functional claims and free beer
Julkaistu Oxford University Press, Oxford : 2022.
Ulkoasutiedot
Sarjamerkintö ei-lisäkirjausmuodossa Journal of Intellectual Property Law & Practice, ISSN 1747-1532 ; 17(1)
Huomautus sisällöstä, tiivistelmä tms. Why functional claims are important ; Biological drugs come in many forms, including modified proteins, nucleic acids and cells. These work in numerous ways: mimicking regulating factors such as agonists or antagonists or assisting, replacing or destroying impaired elements of the body’s own biological pathways, amongst other functions. An advantage of biologics over many traditional small-molecule drugs is that they are targeted directly and precisely at specific causes of disease. At the same time, however, they are characterized by high structural and functional complexity. When it comes to patents for such subject matter, as advancing technology allows more sophisticated biological drugs to be developed, more questions have of course arisen in prosecution and disputes about how established principles of patent law should apply. This has been demonstrated most recently by the addition of a new section of the EPO’s Guidelines for Examination1 in March 2021 dealing with specific issues relating to antibodies, probably the most abundant class of biologics.
Asiasana
Sarjalisäkirjaus - yhtenäistetty nimeke Journal of Intellectual Property Law & Practice, 1747-1532 ; 17(1)
*000 ab a ar
*00117309
*008 s2022||||xxk|||||||||||||||||eng||
*040 $aFI-CUTE$bfin$erda
*0410 $aeng
*1001 $aEngland, Paul,$ekirjoittaja.
*24510$aFunctional claims and free beer /$cPaul England.
*264 1$aOxford :$bOxford University Press,$c2022.
*300 $as. 71–78.
*336 $ateksti$btxt$2rdacontent
*337 $akäytettävissä ilman laitetta$bn$2rdamedia
*338 $anide$bnc$2rdacarrier
*4901 $aJournal of Intellectual Property Law & Practice,$x1747-1532 ;$v17(1)
*520 $aWhy functional claims are important ; Biological drugs come in many forms, including modified proteins, nucleic acids and cells. These work in numerous ways: mimicking regulating factors such as agonists or antagonists or assisting, replacing or destroying impaired elements of the body’s own biological pathways, amongst other functions. An advantage of biologics over many traditional small-molecule drugs is that they are targeted directly and precisely at specific causes of disease. At the same time, however, they are characterized by high structural and functional complexity. When it comes to patents for such subject matter, as advancing technology allows more sophisticated biological drugs to be developed, more questions have of course arisen in prosecution and disputes about how established principles of patent law should apply. This has been demonstrated most recently by the addition of a new section of the EPO’s Guidelines for Examination1 in March 2021 dealing with specific issues relating to antibodies, probably the most abundant class of biologics.
*650 7$alääketeollisuus $0http://www.yso.fi/onto/yso/p11187$2yso/fin
*650 7$apatentit$0http://www.yso.fi/onto/yso/p3069$2yso/fin
*650 7$ateollisoikeus$2yso/fin$0http://www.yso.fi/onto/yso/p3067
*830 0$aJournal of Intellectual Property Law & Practice,$x1747-1532 ;$v17(1)
*852 $hSA-JIPLP
^
Tästä teoksesta ei ole arvioita.
Näpäytä
kun haluat kirjoittaa ensimmäisen arvion.